Medispec and Mabtech announce exclusive partnership to bring EYRA multiplexing platform to India

Medispec India Limited, one of India’s leading channel partners of life science and research instrumentation, has partnered with Swedish biotechnology company Mabtech AB for the exclusive distribution of the EYRA multiplexing platform and EYRAplex kits in India.

This strategic partnership marks a major step toward expanding access to advanced multiplex immunoassay technologies across India’s academic and biopharmaceutical research communities.

Mabtech’s EYRA platform represents a new generation of multiplexing technology designed for high sensitivity, reproducibility, and ease of use in quantitative cytokine analysis. Together with EYRAplex kits, it enables researchers to generate robust, high-quality immunoassay data across multiple analytes from minimal sample volumes — accelerating research in immunology, vaccine development, and cell-based studies.

“Medispec’s scientific expertise, technical support capability, and nationwide reach make them the ideal partner for EYRA in India; together we’re leveraging their on-the-ground strength to accelerate adoption and deliver outstanding customer experience to more labs across India. EYRA and EYRAplex provide high-quality results faster than competing technologies and with a remarkably user-friendly workflow. We are essentially distilling 40 years of Mabtech’s antibody and immunoassay development into a reliable, ready-to-run solution which we are confident will help accelerate immunology research in India", said Carles Solà, Head of Sales, EMEA & APAC, Mabtech AB

With over three decades of experience representing globally respected scientific instrument manufacturers, Medispec brings deep market expertise, technical excellence, and a strong nationwide service network. The company continues to strengthen its portfolio by introducing transformative technologies that empower Indian researchers and enhance scientific productivity.

Vikkalp Chhatbar, Director at Medispec, added, “The EYRA platform represents a new benchmark in multiplex immunoassays — combining simplicity, precision, and scalability. We’re excited to introduce Mabtech’s innovation to Indian researchers and help accelerate breakthroughs in immunology and translational science.”